Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors

NCT01970553 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Specific Advanced Solid Tumors

Interventions

DRUG: lurbinectedin (PM01183)
DRUG: Gemcitabine

Sponsor

PharmaMar